JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm updated estimates following the recent Eylea biosimilar ...

This comprehensive analysis examines Regeneron’s current position, future prospects, and the factors that could shape its trajectory in the coming years. Regeneron focuses on developing and ...

This comprehensive analysis examines Regeneron's current position, recent developments, and future prospects to provide investors with a clear picture of the company's potential. Regeneron ...

This comprehensive analysis examines Regeneron's current position, future prospects, and the factors that could shape its performance in the coming years. Regeneron has demonstrated strong ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc.

Regeneron reported strong Q3 2023 results, driven by the growth of Dupixent and Libtayo, as by Eylea holding up against Vabysmo. Claims by Roche of market share gains have not translated into ...